Lynn Anne Bristol

Array ( [id] => 20288396 [patent_doc_number] => 20250313639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 19/242715 [patent_app_country] => US [patent_app_date] => 2025-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19242715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785608 [patent_doc_number] => 20250059287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 18/942051 [patent_app_country] => US [patent_app_date] => 2024-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18942051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785608 [patent_doc_number] => 20250059287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 18/942051 [patent_app_country] => US [patent_app_date] => 2024-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18942051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077600 [patent_doc_number] => 12351650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Antibodies binding to fibroblast activation protein alpha and death receptor 4 [patent_app_type] => utility [patent_app_number] => 18/755457 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 83 [patent_no_of_words] => 46284 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077600 [patent_doc_number] => 12351650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Antibodies binding to fibroblast activation protein alpha and death receptor 4 [patent_app_type] => utility [patent_app_number] => 18/755457 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 83 [patent_no_of_words] => 46284 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19777415 [patent_doc_number] => 12226435 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19 [patent_app_type] => utility [patent_app_number] => 18/643312 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6840 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19792167 [patent_doc_number] => 12233090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19 [patent_app_type] => utility [patent_app_number] => 18/623246 [patent_app_country] => US [patent_app_date] => 2024-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6885 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651312 [patent_doc_number] => 12173081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => CD19/CD38 multispecific antibodies [patent_app_type] => utility [patent_app_number] => 18/612854 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 14375 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 407 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360899 [patent_doc_number] => 20240262933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => CYTOTOXICITY-INDUCING THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 18/611460 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418549 [patent_doc_number] => 20240294672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => CYTOTOXICITY-INDUCING THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 18/590651 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18590651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692875 [patent_doc_number] => 20250011420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => PROTEINS THAT BIND SP17 INCLUDING FULLY-HUMAN ANTI-SP17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/408414 [patent_app_country] => US [patent_app_date] => 2024-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18408414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232163 [patent_doc_number] => 20240189354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 18/393322 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083166 [patent_doc_number] => 20240109967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => CANINE MONOCLONAL ANTIBODIES AGAINST CANINE CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) [patent_app_type] => utility [patent_app_number] => 18/491182 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265402 [patent_doc_number] => 20240209101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING [patent_app_type] => utility [patent_app_number] => 18/464998 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921355 [patent_doc_number] => 20240024359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 [patent_app_type] => utility [patent_app_number] => 18/238210 [patent_app_country] => US [patent_app_date] => 2023-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921355 [patent_doc_number] => 20240024359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 [patent_app_type] => utility [patent_app_number] => 18/238210 [patent_app_country] => US [patent_app_date] => 2023-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921355 [patent_doc_number] => 20240024359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 [patent_app_type] => utility [patent_app_number] => 18/238210 [patent_app_country] => US [patent_app_date] => 2023-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921355 [patent_doc_number] => 20240024359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 [patent_app_type] => utility [patent_app_number] => 18/238210 [patent_app_country] => US [patent_app_date] => 2023-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940286 [patent_doc_number] => 12312408 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Multispecific anti-TCR delta variable 1 antibodies [patent_app_type] => utility [patent_app_number] => 18/451047 [patent_app_country] => US [patent_app_date] => 2023-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 91 [patent_figures_cnt] => 176 [patent_no_of_words] => 132557 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 412 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844521 [patent_doc_number] => 20230406925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => SIGLEC-8 BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/361184 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361184 [rel_patent_id] =>[rel_patent_doc_number] =>)